In particular, lymphoma samples with concurrent myeloid disease showed high variations in IDH2 expression compared with the R-AITL samples, which was consistent with the high differences in expression that were also found in the proteomic analysis (Figure 2C). The gene discussed is IDH2; the disease is lymphoma.